Deutsche Bank is out with its report today on Medicis Pharmaceutical MRX, maintaining Buy.
In a note to clients, Deutsche Bank writes, "The outlook for Medicis's flagship Solodyn franchise has improved significantly over the past six months – based on a strong switch thus far to the new protected doses and considerable strengthening of the patent position. We continue to see Medicis capable of generating long-term mid-teens EPS growth, driven by its acne and aesthetics brands and its emerging development pipeline."
Deutsche Bank maintains a $35 PT on MRX.
At the time of posting, shares of MRX were trading at $28.05, up 0.18% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in